State Street SPDR S&P Biotech ETF
XBI SectorUpdated: Apr 6, 2026, 12:07 UTC
Key Metrics
Top 10 Holdings
| Holding | Ticker | Weight | Bar |
|---|---|---|---|
| Moderna Inc | MRNA | 2.25% | |
| Roivant Sciences Ltd Ordinary Shares | ROIV | 1.74% | |
| Vaxcyte Inc Ordinary Shares | PCVX | 1.73% | |
| Arcellx Inc | ACLX | 1.66% | |
| Revolution Medicines Inc Ordinary Shares | RVMD | 1.59% | |
| Praxis Precision Medicines Inc Ordinary Shares | PRAX | 1.57% | |
| Amgen Inc | AMGN | 1.5% | |
| Gilead Sciences Inc | GILD | 1.49% | |
| Amicus Therapeutics Inc | FOLD | 1.48% | |
| Mirum Pharmaceuticals Inc | MIRM | 1.41% |
Sector Allocation
About This ETF
The State Street SPDR S&P Biotech ETF (XBI) is a Sector ETF with an expense ratio (TER) of 0.35% and $8.1B in assets under management., with its largest holdings being Moderna Inc, Roivant Sciences Ltd Ordinary Shares, Vaxcyte Inc Ordinary Shares. The ETF currently yields 0.35% in dividends. Year-to-date, XBI has returned +6.12%.
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Where can I buy XBI?
Compare the best brokers for ETF savings plans — low fees, trusted providers, fully regulated.